Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.


Options:
A: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo
B: Arm Label: QMF149 150/160 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol acetate/Mometasone furoate | Arm Label: QMF149 150/320 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol acetate/Mometasone furoate | Arm Label: MF 400 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate | Arm Label: Salmeterol /fluticasone 50/500 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol xinafoate/fluticasone propionate | Arm Label: MF 800 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone furoate | Intervention Type: DRUG; Name: Indacaterol acetate/Mometasone furoate; Assigned to Arm(s): QMF149 150/160 µg, QMF149 150/320 µg | Intervention Type: DRUG; Name: Mometasone furoate; Assigned to Arm(s): MF 400 µg, MF 800 μg | Intervention Type: DRUG; Name: Salmeterol xinafoate/fluticasone propionate; Assigned to Arm(s): Salmeterol /fluticasone 50/500 μg
C: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate, Drug: Vilanterol | Arm Label: FP/S OR BUD/F; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Salmeterol, Drug: Budesonide, Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): FP/S OR BUD/F

Answer: A